Core Viewpoint - Autonomix Medical, Inc. has developed innovative technologies aimed at revolutionizing the diagnosis and treatment of diseases involving the nervous system, with a focus on pancreatic cancer-related pain management [2][4]. Group 1: Patent and Technology Development - The company has a growing global patent portfolio with over 120 patents, including 80 issued patents and over 40 pending applications [3][5]. - The recently issued U.S. patent 12,064,256 (the "256 patent") covers systems and methods for treating cancer and augmenting organ function, specifically targeting pancreatic cancer-related pain [3][4]. - Autonomix's first-in-class catheter-based microchip sensing array technology can detect and differentiate neural signals with approximately 3,000 times greater sensitivity than existing technologies [2][6]. Group 2: Clinical Studies and Results - A preclinical study demonstrated a statistically significant reduction in metastases and tumor mass through targeted nerve ablation, indicating the potential impact of neural pathways in pancreatic cancer [4][6]. - The ongoing proof-of-concept human clinical trial is focused on pain reduction from the ablation of target nerves near the pancreas, with plans for additional studies to evaluate the clinical application of the technology [4][10]. Group 3: Future Directions and Applications - The company aims to explore the potential of its ablation technology to slow pancreatic cancer growth and metastasis based on positive preclinical results [4][10]. - The technology platform is designed to address various disease categories, including chronic pain management, cardiology, and hypertension, beyond its initial focus on cancer pain [10].

Growing global patent portfolio to over 120 patents with 80 issued patents and over 40 pending patent applications Previously completed preclinical study evaluating targeted nerve ablation demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass THE WOODLANDS, TX, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutio ...

Core Insights - Autonomix Medical, Inc. is advancing its first-in-class catheter-based sensing technology and is on track to submit an Investigational Device Exemption (IDE) in anticipation of FDA approval, with a pivotal clinical trial planned for 2025 [1][3] - The company has appointed Julie Manchester as Vice President of Regulatory Affairs and Quality, bringing over 15 years of experience in the medical device and biotech sectors [2][4] - The technology aims to revolutionize the diagnosis and treatment of diseases involving the nervous system, with initial focus on treating pancreatic cancer pain [6][7] Company Developments - Autonomix has successfully completed animal testing and design lock for its RF technology, and is building the necessary team and infrastructure to support clinical and regulatory initiatives [1][3] - The company is preparing for key milestones in 2025, which are expected to significantly impact its growth and development [3] - An inducement stock option for 19,500 shares was granted to Ms. Manchester as part of her employment compensation [4][5] Technology Overview - The company's platform technology includes a catheter-based microchip sensing array that can detect neural signals with approximately 3,000 times greater sensitivity than existing technologies [6] - The initial application of this technology is aimed at addressing pain associated with pancreatic cancer, a condition currently lacking reliable treatment options [7] - The technology has the potential to address a wide range of indications, including cardiology and chronic pain management [7]

First-in-class catheter-based sensing technology designed to sense neuronal signals that indicate pain or disease and destroy those nerves at the source Company expects to submit an Investigational Device Exemption (“IDE”), and if approved, will commence a pivotal clinical trial to support a De Novo application for FDA approval THE WOODLANDS, TX, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative t ...

Core Viewpoint - Autonomix Medical, Inc. has successfully closed a public offering of common stock and pre-funded warrant units, raising approximately $10.0 million to support its clinical trials and research initiatives [1][3]. Group 1: Offering Details - The equity offering consisted of 615,500 common stock units and 917,596 pre-funded warrant units, priced at $6.54 and $6.539 per unit respectively [2]. - Each common stock unit and pre-funded warrant unit included one share of common stock and one Series A Warrant, which has an exercise price of $6.54 and expires five years from issuance [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for funding clinical trials, research and development, intellectual property development, and working capital [3]. Group 3: Company Overview - Autonomix Medical is focused on innovative technologies for diagnosing and treating diseases of the nervous system, featuring a catheter-based microchip sensing array with significantly enhanced sensitivity [6]. - The company is initially targeting pain management, particularly for pancreatic cancer, and aims to address various conditions across a wide disease spectrum [7].

THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced the pricing of an underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately $9.0 million prior to deducting underwriting discounts and commissions and offering expenses. The equity offering is comprised of 1,376,287 commo ...

[Form 8-K Current Report](index=1&type=section&id=Form%208-K) This current report details significant events, including financial results and related exhibits [Item 2.02. Results of Operations and Financial Condition](index=1&type=section&id=Item%202.02.%20Results%20of%20Operations%20and%20Financial%20Condition) Autonomix Medical, Inc. announced its financial results for the three and six months ended September 30, 2024, via a press release - The company announced financial results for the three and six months ended September 30, 2024[2](index=2&type=chunk) - The announcement was made through a press release dated November 11, 2024, attached as Exhibit 99.1 and incorporated by reference[2](index=2&type=chunk) [Item 9.01. Financial Statements and Exhibits](index=3&type=section&id=Item%209.01.%20Financial%20Statements%20and%20Exhibits) This section details the exhibits accompanying the Form 8-K report, primarily the press release with financial results | Exhibit No. | Exhibit Description | | :--- | :--- | | 99.1 | Press Release dated November 11, 2024 | | 104 | Cover page Interactive Data File (embedded within the Inline XBRL document) |

Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6 weeks post-procedure Company’s first-in-class technology has demonstrated significant, enduring reduction in pain and improvement in quality of life in ongoing PoC study to date THE WOODLANDS, TX, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical dev ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to__________ Commission file number 001-41940 Autonomix Medical, Inc. (Exact Name of Registrant as Specified in Its Charter) De ...

Access the Virtual Investor "What This Means" Segment here THE WOODLANDS, TX, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nervetargeted treatments, today announced that it recently participated in a Virtual Investor "What This Means" segment. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company's recently announced 4-6 week positive follow-up data, f ...